Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison

References

• American Cancer Society. Types of B-cell lymphoma [cited 2021 Jun 22]. Available from: https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/b-cell-lymphoma.html
   Google Scholar
• World Health Organization. Diffuse large B-cell lymphoma; 2014 [cited 2020 Apr 4]. Available from: http://www.who.int/selection_medicines/committees/expert/20/applications/DiffuseLargeBCellLymphoma.pdf
   Google Scholar
• National Cancer Institute. Cancer Stat Facts: NHL—diffuse large B-cell lymphoma (DLBCL); 2021 [cited 2021 Feb 24]. Available from: https://seer.cancer.gov/statfacts/html/dlbcl.html
   Google Scholar
• Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011(1):498–505.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
   PubMed Web of Science ®Google Scholar
• Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the international CORAL study. Bone Marrow Transplant. 2016;51(1):51–57.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190.
   PubMed Web of Science ®Google Scholar
• Crump M. Management of relapsed diffuse large B-cell lymphoma. Hematol Oncol Clin North Am. 2016;30(6):1195–1213.
   PubMed Web of Science ®Google Scholar
• Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32(31):3490–3496.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematology Am Soc Hematol Educ Program. 2016;2016(1):366–378.
   PubMed Web of Science ®Google Scholar
• Chaganti S, Illidge T, Barrington S, et al. Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol. 2016;174(1):43–56.
   PubMed Web of Science ®Google Scholar
• Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl_5):v116–v125.
   PubMedGoogle Scholar
• Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852.
   PubMed Web of Science ®Google Scholar
• Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration (FDA). Highlights of prescribing information: YESCARTA™ (axicabtagene ciloleucel); 2017 [cited 2021 Feb 24]. Available from: https://www.fda.gov/media/108377/download
   Google Scholar
• United States Food and Drug Administration (FDA). Highlights of prescribing information: KYMRIAH™ (tisagenlecleucel); 2018 [cited 2019 Oct 28]. Available from: https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert.KYMRIAH.pdf
   Google Scholar
• United States Food and Drug Administration (FDA). Highlights of prescribing information: BREYANZI™ (lisocabtagene maraleucel); 2021 [cited 2021 Feb 25]. Available from: https://www.fda.gov/media/145711/download
   Google Scholar
• Jaeger U, Bishop MR, Salles G, et al. Myc expression and tumor-infiltrating t cells are associated with response in patients (pts) with relapsed/refractory diffuse large b-cell lymphoma (r/r DLBCL) treated with tisagenlecleucel in the JULIET trial. Blood. 2020;136(Supplement 1):48–49.
   Google Scholar
• Oluwole OO, Jansen JP, Lin VW, et al. Comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed/refractory large B cell lymphoma. Biol Blood Marrow Transplant. 2020;26(9):1581–1588.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li J, Ma Q, et al. Letter to the editor regarding “comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed/refractory large B cell lymphoma”. Biol Blood Marrow Transplant. 2020;26(12):e333–e334.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li J, Ma Q, et al. A review of two regulatory approved anti-CD19 CAR T-cell therapies in diffuse large B-cell lymphoma: why are indirect treatment comparisons not feasible? Adv Ther. 2020;37(7):3040–3058.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
   PubMed Web of Science ®Google Scholar
• Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32(27):3048–3058.
   PubMed Web of Science ®Google Scholar
• Mitchell M, Muftakhidinov B, Winchen T. Engauge Digitizer Software [cited 2021 Feb 26]. Available from: http://markummitchell.github.io/engauge-digitizer
   Google Scholar
• Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947.
   PubMed Web of Science ®Google Scholar
• Phillippo DM, Ades AE, Dias S, et al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE [cited 2021 Feb 25]. Available from: http://www.nicedsu.org.uk/wp-content/uploads/2017/05/Population-adjustment-TSD-FINAL.pdf
   Google Scholar
• Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935–945.
   PubMed Web of Science ®Google Scholar
• Maloney DG, Kuruvilla J, Fox CP, et al. 2116 Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) vs axicabtagene ciloleucel (axi-cel) and tisagenlecleucel in relapsed/refractory (r/r) large B-cell lymphoma (LBCL). 2020 American Society of Hematology (ASH) Annual Meeting; 2020 December 5–8. (virtual).
   Google Scholar
• Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47–62.
   PubMed Web of Science ®Google Scholar
• Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34–48.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Maziarz RT, Rusch ES, et al. Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv. 2020;4(7):1432–1439.
   PubMed Web of Science ®Google Scholar
• Si S, Teachey DT. Spotlight on tocilizumab in the treatment of CAR-T cell-induced cytokine release syndrome: clinical evidence to date. Ther Clin Risk Manag. 2020;16:705–714.
   PubMed Web of Science ®Google Scholar
• Riedell PA, Walling C, Nastoupil LJ, et al. A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B-cell lymphomas. Blood. 2019;134(Supplement_1):1599–1599.
   Web of Science ®Google Scholar
• Jaglowski S, Hu Z-H, Zhang Y, et al. Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): real world experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry. Blood Adv. 2019;134(Supplement_1):766–766.
   Google Scholar
• Pasquini MC, Hu Z-H, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414–5424.
   PubMed Web of Science ®Google Scholar